Background. Left Bundle bracnch area pacing has become the procedure of choice for various indications including atrioventricular block and considered to be physiologic modality of pacing compare to RV apex pacing. Objectives. The purpose of this study was to assess ventricular activation and synchrony in patients with LBBAP device using ECG imaging. Methods. 25 consecutive patients underwent an LBBAP device implantation have been included in the study. ECG and ECGI analysys have been performed the day after implantation. Native and paced QRS, LVAT, RVAT and V1AD were calculated using ECG. TVACT, LVACT, LVACTi, RVACT, RVACTi and IVDS were calculated based on ECGI. All patients were followed up for at least 1 year. Results All patients were divided in 2 groups (wide and narrow QRS) based on intrinsic ECG and then based on paced ECG parameters. Study showed that for initially narrow QRS group activation time and synchrony during pacing was comparable to native. In wide QRS group these parameters were significantly improved. For paced rhythm analysis classic ECG LBBAP parameters (paced QRS and LVAT) were not sufficient to properly evaluate the ventricular activation for paced rhythm. Discordance between ECG and ECGI analysys was identified. Two additional 12 lead ECG parameters predicting the ECGI measurements were found. Follow up did not show any worsening of device parameters or Echographic and ECG signs of ventricular dissynchrony Conclusions ECG imaging can bring a significant value into assessing the efficacy of new pacing modalities and provide much more data for precise determination of implantation outcome including detailed activation assessment and comparison to intrinsic conduction. Key ECGI values confirming proper ventricular activation have been defined and corresponding 12 lead parameters were also identified.

Dr Almorad receives compensation for teaching from Biosense Webster, Dr. de Asmundis has received research grants on behalf of the center from Biotronik, Medtronic, Abbott, LivaNova, Boston Scientific, AtriCure, Philips, and Acutus; and has received compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik, Livanova, Boston Scientific, Atricure, and Acutus Medical Daiichi Sankyo. Dr. Chierchia has received compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik, Boston Scientific, and Acutus Medical. Dr. La Meir has been a consultant for Atricure. Mr Zeng and Dr. Eltsov are receiving compensations from Medtronic.

NCT05401851

This research received no external funding.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study had been approved by ethics committee of University Hospital of Brussels (UZ Brussel)

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

The data that support the findings of this study are available from the corresponding author upon reasonable request.